Skip to main navigation
Axsome Corporate Homepage
  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Overview
    • Products Overview  down arrow
      • All
      • Overview
      • Auvelity® (dextromethorphan-bupropion)
      • Sunosi® (solriamfetol)
      • Symbravo® (meloxicam and rizatriptan)
    • Pipeline Overview  down arrow
      • All
      • Overview
      • AXS-05
      • AXS-12
      • AXS-14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer’s Disease Agitation
    • Excessive Daytime Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Axsome Corporate Homepage
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information Canada
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts & Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Overview
    • Current Opportunities

Webcasts & Presentations

Webcasts & Presentations

Webcasts & Presentations

Presentations

Date Title
May 4, 2026
First Quarter 2026 Corporate Presentation
May 1, 2026
AUVELITY in Agitation Associated with Dementia due to Alzheimer’s Disease FDA Approval Call Presentation
July 21, 2025
Frontiers in Brain Health R&D Day

Webcasts

Date Event Supporting Materials
May 19, 2026 at 1:35 PM EDT
2026 RBC Capital Markets Global Healthcare Conference
Click here for Webcast
May 12, 2026 at 11:40 AM EDT
BofA Securities 2026 Health Care Conference
Click here for Webcast
May 04, 2026 at 8:00 AM EDT
Axsome First Quarter 2026 Financial Results
Click here for Webcast
May 01, 2026 at 8:00 AM EDT
AUVELITY in Agitation Associated with Dementia due to Alzheimer’s Disease FDA Approval Call
Click here for Webcast
July 21, 2025 at 11:00 AM EDT
Axsome Frontiers in Brain Health R&D Day
Click here for webcast
  • About Axsome
    • All
    • Overview
    • Management Team
    • Board of Directors
    • Intellectual Property
    • State Disclosures
  • Portfolio
    • All
    • Products Overview
    • Products Overview
    • Auvelity™ (dextromethorphan-bupropion)
    • Sunosi® (solriamfetol)
    • Symbravo® (meloxicam and rizatriptan)
    • Pipeline Overview
    • AXS‑05
    • AXS‑12
    • AXS‑14
  • Conditions
    • All
    • Overview
    • Depression
    • Migraine
    • Alzheimer's
      Disease Agitation
    • Excessive Daytime
      Sleepiness
    • Narcolepsy
    • Fibromyalgia
    • Smoking Cessation
  • Science
    • All
    • Overview
    • Medical Information U.S.
    • Medical Information International
    • Publications
  • Investors
    • All
    • Overview
    • Corporate Governance
    • Stock Information
    • Financial Information
    • News & Events
    • Webcasts &
      Presentations
    • Analyst Coverage
    • Shareholder Services
  • Careers
    • All
    • Careers
    • Current Opportunities
Axsome
  • Contact Us
  • Privacy Notice
  • Terms of Use
  • See Axsome Therapeutics on LinkedIn

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics,Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2026 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, New York, NY, 10007 info@axsome.com